statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $38.16, but opened at $35.29. Belite Bio shares last...

Belite Bio (NASDAQ:BLTE) Shares Gap Down to $38.16

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Belite Bio announces PMDA submission of Tinlarebant for trial in Japan

Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Belite Bio, Inc (NASDAQ:BLTE  Free Report)  Analysts at HC Wainwright raised their Q1 2024 EPS estimates for Belite Bio in a research report issued to clients and investors on...

Q1 2024 EPS Estimates for Belite Bio, Inc Raised by HC Wainwright (NASDAQ:BLTE)

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio reports Q4 EPS (27c), consensus (30c)

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Belite Bio participates in a conference call with Benchmark

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Volume	32,733.00
52-Wk High	$48.60
52-Wk Low	$11.00

BLTE Belite Bio Inc

About

Feed

News

Sentiment

Fundamentals